TLSI vs. ANGO, SGHT, UTMD, LUNG, INO, RCEL, CERS, ARAY, CVRX, and LYRA
Should you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include AngioDynamics (ANGO), Sight Sciences (SGHT), Utah Medical Products (UTMD), Pulmonx (LUNG), Inovio Pharmaceuticals (INO), AVITA Medical (RCEL), Cerus (CERS), Accuray (ARAY), CVRx (CVRX), and Lyra Therapeutics (LYRA). These companies are all part of the "surgical & medical instruments" industry.
TriSalus Life Sciences (NASDAQ:TLSI) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.
TriSalus Life Sciences has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.
AngioDynamics received 361 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users.
In the previous week, TriSalus Life Sciences had 1 more articles in the media than AngioDynamics. MarketBeat recorded 1 mentions for TriSalus Life Sciences and 0 mentions for AngioDynamics. TriSalus Life Sciences' average media sentiment score of 0.00 equaled AngioDynamics'average media sentiment score.
TriSalus Life Sciences has a net margin of 0.00% compared to AngioDynamics' net margin of -60.21%. TriSalus Life Sciences' return on equity of 0.00% beat AngioDynamics' return on equity.
2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 89.4% of AngioDynamics shares are held by institutional investors. 76.2% of TriSalus Life Sciences shares are held by insiders. Comparatively, 5.1% of AngioDynamics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
AngioDynamics has a consensus target price of $14.25, indicating a potential upside of 146.11%. Given AngioDynamics' higher possible upside, analysts clearly believe AngioDynamics is more favorable than TriSalus Life Sciences.
AngioDynamics has higher revenue and earnings than TriSalus Life Sciences.
Summary
AngioDynamics beats TriSalus Life Sciences on 8 of the 13 factors compared between the two stocks.
Get TriSalus Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TriSalus Life Sciences Competitors List
Related Companies and Tools
